Andrews, Gavin

Curran, Rhonda

Donnelly, Louise

Kett, Victoria

Malcolm, Karl

Morrow, Ryan

Shattock, R.J.

Woolfson, David

Queen's University Belfast Research Portal

Stable lyophilised gel vehicles for vaginal administration ofrecombinant C-clade HIV-1 trimeric CN54gp140Donnelly, L., Curran, R., Morrow, R., Kett, V., Andrews, G., Malcolm, K., ... Shattock, R. J. (2009). Stablelyophilised gel vehicles for vaginal administration of recombinant C-clade HIV-1 trimeric CN54gp140.Retrovirology, 6(S3), 156. DOI: 0.1186/1742-4690-6-S3-P156Published in:RetrovirologyQueen's University Belfast - Research Portal:Link to publication record in Queen's University Belfast Research PortalGeneral rightsCopyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or othercopyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associatedwith these rights.Take down policyThe Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made toensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in theResearch Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.Download date:15. Feb. 2017BioMed CentralPage 1 of 1(page number not for citation purposes)RetrovirologyOpen AccessPoster presentationP11-11. Stable lyophilised gel vehicles for vaginal administration of recombinant C-clade HIV-1 trimeric CN54gp140L Donnelly*1, RM Curran1, RJ Morrow1, VL Kett1, GP Andrews1, RK Malcolm1, AD Woolfson1 and RJ Shattock2Address: 1School of Pharmacy, Queens University Belfast, Belfast, UK and 2St George's University of London, London, UK* Corresponding author    BackgroundWith an effective vaccine being sought for the preventionof HIV transmission, current focus is upon a mucosal vac-cine strategy providing protection at the viral point ofentry. The full potential of these vaccines can only be real-ised with the development of successful delivery systemswhich are also capable of providing an environment con-ducive to antigen stability. Previously, rheologically struc-tured vehicles (RSVs) were formulated to include therecombinant C-clade HIV-1 envelope proteinCN54gp140, and intra-vaginal immunisation in rabbitsinduced significant systemic IgG and specific IgG and IgAin genital tract secretions. However, CN54gp140 stabilitywithin these aqueous formulations remains a concern.Here we investigate the formulation of CN54gp140within modified lyophilised RSV matrices as a means ofproviding enhanced protein stabilisation.MethodsRSV formulations were prepared comprising mucoadhe-sive (polycarbophil, sodium carboxymethylcellulose) andvaginal fluid absorbing (polyvinylpyrrolidine) compo-nents. Using rheological analyses in combination withdispensing studies, formulations having appropriate flowproperties were chosen for lyophilisation. In vitro releasetesting of the lyophilised CN54gp140 formulations wereinvestigated in PBST, and following prolonged storage at37°C the antigenicity of CN54gp140 from the lyophilisedRSVs were analysed by ELISA. The antigen CN54gp140stability profiles of these formulations were compared tothe original aqueous RSV.ResultsCN54gp140 was found to be uniformly distributedwithin the lyophilised products and exhibited a sustainedrelease profile over an 8 hour period during which thelyophilised 'tablet' underwent complete dissolution in thesurrounding media. While recovery of CN54gp140 fromthe aqueous RSV diminished over 9 days, lyophilisationshowed no loss in CN54gp140 antigenicity over 67 daysstorage.ConclusionFormulation of CN54gp140 within a lyophilised gelmatrix is shown to have a stabilising effect on the antigenwhile preserving its sustained release capacity. Such amucosal vaccine delivery system may offer numerousadvantages including ease of use, long-term stability andcold chain avoidance.from AIDS Vaccine 2009Paris, France. 19–22 October 2009Published: 22 October 2009Retrovirology 2009, 6(Suppl 3):P156 doi:10.1186/1742-4690-6-S3-P156<supplement> <title> <p>AIDS Vaccine 2009</p> </title> <editor>Anna Laura Ross</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S3-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf</url> </supplement>This abstract is available from: http://www.retrovirology.com/content/6/S3/P156© 2009 Donnelly et al; licensee BioMed Central Ltd. 

Stable lyophilised gel vehicles for vaginal administration of recombinant C-clade HIV-1 trimeric CN54gp140

Stable lyophilised gel vehicles for vaginal administration of recombinant C-clade HIV-1 trimeric CN54gp140

Abstract

Similar works

Full text

Available Versions

Queen's University Belfast Research Portal